Antisense Therapeutics Ltd (ANP) - Financial and Strategic SWOT Analysis Review

October 2021 | 41 pages | ID: AAD263A3059EN
GlobalData

Abstracts

Antisense Therapeutics Ltd (ANP) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

• Business description – A detailed description of the company’s operations and business divisions.
• Corporate strategy – Analyst’s summarization of the company’s business strategy.
• SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
• Company history – Progression of key events associated with the company.
• Major products and services – A list of major products, services and brands of the company.
• Key competitors – A list of key competitors to the company.
• Key employees – A list of the key executives of the company.
• Executive biographies – A brief summary of the executives’ employment history.
• Key operational heads – A list of personnel heading key departments/functions.
• Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
• Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
• Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

Antisense Therapeutics Ltd (Antisense Therapeutics) is clinical staged biopharmaceutical company which focuses on the discovery, development and commercialization of second-generation antisense pharmaceuticals for various medical conditions that have large unmet medical needs. It focuses on the development of antisense drugs in the areas of immunology disorders and rare diseases such as multiple sclerosis (MS) among others. Antisense Therapeutics’s development pipeline comprises of ATL1103 for potential treatment for growth hormone disorders such as Acromegaly; ATL1102 (injection), which reduces brain lesions is being development for the treatment of multiple sclerosis. ATL1102 is also being developed for the treatment of duchenne muscular dystrophy (DMD). Antisense Therapeutics is headquartered in Toorak, Victoria, Australia.

Antisense Therapeutics Ltd Key Recent Developments

Aug 24,2021: ANP to participate in PPMD development of new Community-Led Duchenne Guidance for FDA
Jul 29,2021: Antisense Therapeutics: Quarterly activities report & appendix 4C
Jul 28,2021: Antisense Therapeutics transitions to new Board Chair
Mar 22,2021: Antisense Therapeutics appoints new Non-executive Director
Apr 21,2020: Antisense Therapeutics: Quarterly Update & Appendix 4C

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.

• The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.

• The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.

• Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.

• Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.

• Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company

Contents

SECTION 1 - ABOUT THE COMPANY

Antisense Therapeutics Ltd - Key Facts
Antisense Therapeutics Ltd - Key Employees
Antisense Therapeutics Ltd - Key Employee Biographies
Antisense Therapeutics Ltd - Major Products and Services
Antisense Therapeutics Ltd - History
Antisense Therapeutics Ltd - Locations And Subsidiaries
Head Office

SECTION 2 – COMPANY ANALYSIS

Company Overview
Antisense Therapeutics Ltd - Business Description
Antisense Therapeutics Ltd - Corporate Strategy
Antisense Therapeutics Ltd - SWOT Analysis
SWOT Analysis - Overview
Antisense Therapeutics Ltd - Strengths
Antisense Therapeutics Ltd - Weaknesses
Antisense Therapeutics Ltd - Opportunities
Antisense Therapeutics Ltd - Threats
Antisense Therapeutics Ltd - Key Competitors

SECTION 3 – COMPANY FINANCIAL RATIOS

Financial Ratios - Capital Market Ratios
Financial Ratios - Annual Ratios
Performance Chart
Financial Performance
Financial Ratios - Interim Ratios
Financial Ratios - Ratio Charts

SECTION 4 – COMPANY’S LIFESCIENCES FINANCIAL DEALS AND ALLIANCES

Antisense Therapeutics Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021
Antisense Therapeutics Ltd, Pharmaceuticals & Healthcare, Deals By Type, 2015 to YTD 2021
Antisense Therapeutics Ltd, Recent Deals Summary

SECTION 5 – COMPANY’S RECENT DEVELOPMENTS

Aug 24, 2021: ANP to participate in PPMD development of new Community-Led Duchenne Guidance for FDA
Jul 29, 2021: Antisense Therapeutics: Quarterly activities report & appendix 4C
Jul 28, 2021: Antisense Therapeutics transitions to new Board Chair
Mar 22, 2021: Antisense Therapeutics appoints new Non-executive Director
Apr 21, 2020: Antisense Therapeutics: Quarterly Update & Appendix 4C
Feb 27, 2020: Antisense Therapeutics announces appointment of US-based consultant medical director

SECTION 6 – APPENDIX

Methodology
Ratio Definitions
About GlobalData
Contact Us
Disclaimer

List Of Tables

LIST OF TABLES

Antisense Therapeutics Ltd, Key Facts
Antisense Therapeutics Ltd, Key Employees
Antisense Therapeutics Ltd, Key Employee Biographies
Antisense Therapeutics Ltd, Major Products and Services
Antisense Therapeutics Ltd, History
Antisense Therapeutics Ltd, Key Competitors
Antisense Therapeutics Ltd, Ratios based on current share price
Antisense Therapeutics Ltd, Annual Ratios
Antisense Therapeutics Ltd, Annual Ratios (Cont...1)
Antisense Therapeutics Ltd, Interim Ratios
Antisense Therapeutics Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021
Antisense Therapeutics Ltd, Pharmaceuticals & Healthcare, Deals By Type, 2015 to YTD 2021
Antisense Therapeutics Ltd, Recent Deals Summary
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios

List Of Figures

LIST OF FIGURES

Antisense Therapeutics Ltd, Performance Chart (2017 - 2021)
Antisense Therapeutics Ltd, Ratio Charts
Antisense Therapeutics Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021
Antisense Therapeutics Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2015 to YTD 2021